Abstract
Isoniazid (INH) therapy is associated with a significant incidence of idiosyncratic liver failure. We recently reported eight cases of INH-induced liver failure in which patients had antidrug and anticytochrome P450 antibodies. However, it was unclear what role these antibodies play in the mechanism of INH-induced liver injury. Here, we report that the dominant isotype of anti-INH antibodies was IgG, with IgG3 being the dominant subtype. IgG3 antibodies are associated with a Th1-type immune response and fix complement. IgG3 antibodies have been associated with other forms of liver injury and may play a pathogenic role in INH-induced liver injury. © 2014 American Chemical Society.
Cite
CITATION STYLE
Metushi, I. G., Lee, W. M., & Uetrecht, J. (2014). IgG3 is the dominant subtype of anti-isoniazid antibodies in patients with isoniazid-induced liver failure. Chemical Research in Toxicology, 27(5), 738–740. https://doi.org/10.1021/tx500108u
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.